MoleculeMind
AI protein structure prediction and design (MoleculeOS, MMFold, MMDesign) sold to drugmakers and industrial-enzyme users, with a few in-house early programs.
Money and evidence
Latest round, Series A (extension), 2026-06-17: the record then held no research entry for the company. The first research entry is dated 2026-09-11; the highest level so far is 2 (Computed).
Rounds and research, on one timeline
- 2026-09-11Research
Level 2 · Computed
MoleculeMind's QuantaMind, a learned force field for reactive molecular dynamics, appears in Science Advances: near-DFT accuracy on systems of about ten thousand atoms
Reactive simulation of a whole enzyme is what protein design lacks, but every check here is against quantum-chemistry calculations, not a measured reaction rate.
- 2026-06-17Series A (extension)Round
A-series cumulative total over US$100 million
For: global industrialisation of its protein-design stack
Commercial roll-out
No lead named; 'over $100M' is cumulative for the A series, not this tranche alone.
Lanqiao CapitalPudong Venture CapitalCOFCO Emerging Industry FundOriental Fortune CapitalFosun CapitalSepax TechnologiesGuofang CapitalInfinity GroupCaixin CapitalZhengdingExisting investor · Cathay BiotechExisting investor · Xinhang Capital
On the deal: Bohao Huang (Founder, Lanqiao Capital); Chen Yang (President, Cathay Biotech); Huawei Chen (Partner, Oriental Fortune Capital); Lijuan Ye (Managing Director, Fosun Capital); Xueying Huang (Chairman, Sepax Technologies)
- 2024-09-13Series ARound
several hundred million yuan
For: team, protein foundation model and MoleculeOS
HiringModels and platform
Co-lead · Xienuo InvestmentCo-lead · Shenzhen Capital GroupSenseTime Guoxiang CapitalJiuyi Investment
On the deal: Xiaolin Wei (Founding Partner, investment committee chair, Xienuo Investment); Yi Zhou (General manager, health industry investment dept., Shenzhen Capital Group); Yutong Hu (Managing Partner, SenseTime Guoxiang Capital)
- 2023-02-20Pre-ARound
over 100 million yuan
For: MoleculeOS development; biologics design and synthetic biology
Models and platform
The release calls it a strategic investment; the headline calls it Pre-A.
Lead · Cathay BiotechLenovo Capital ✓Sequoia China
On the deal: Xiucai Liu (Chairman, Cathay Biotech); Yunxia Yang (Partner, Sequoia China); Zhiqiang He (SVP of Lenovo Group, president of Lenovo Capital, Lenovo Capital)
- 2022-04-18AngelRound
tens of millions of US dollars
For: team, platform and productising research
HiringModels and platformCommercial roll-out
Lead · Sequoia ChinaBaidu Ventures ✓Life Garden Venture FundXinhang CapitalWeilai Qichuang
Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.
On the investors' own sites
Investors that name this company on their own site, in a portfolio or their own announcement. A ✓ in a round marks the same investor.
- Baidu Venturesbaidu-ventures.com ↗
- Lenovo Capitalcapital.lenovo.com ↗
Its investors also backed
Other companies on this page whose rounds name the same investor.
- HSG (Sequoia China)Anew Labs, METiS TechBio, Insilico Medicine
- Baidu VenturesInsilico Medicine, DP Technology, Deep Principle
- Guofang CapitalBioGeometry, Gaowei Yiyao
- Lenovo CapitalDP Technology, Deep Principle
- Shenzhen Capital GroupOptoSeeker
- Fosun CapitalSoge Intelligent Computing